Published in Stat Appl Genet Mol Biol on December 19, 2004
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci (2009) 1.89
Comments on the analysis of unbalanced microarray data. Bioinformatics (2009) 1.66
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41
False discovery rate paradigms for statistical analyses of microarray gene expression data. Bioinformation (2007) 1.07
Internal validation inferences of significant genomic features in genome-wide screening. Comput Stat Data Anal (2009) 0.85
Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. JAMA Neurol (2015) 0.83
Literature aided determination of data quality and statistical significance threshold for gene expression studies. BMC Genomics (2012) 0.81
The Beta-Binomial Distribution for Estimating the Number of False Rejections in Microarray Gene Expression Studies. Comput Stat Data Anal (2009) 0.78
A Phenotype-Driven Dimension Reduction (PhDDR) approach to integrated genomic association analyses. Conf Proc IEEE Eng Med Biol Soc (2011) 0.75
Exploratory Failure Time Analysis in Large Scale Genomics. Comput Stat Data Anal (2016) 0.75
Integration of diverse statistical evidence of gene-trait association in systems biology studies. Chem Biodivers (2012) 0.75
Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia (2017) 0.75
Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics (2017) 0.75
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2006) 3.04
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A (2009) 2.72
A molecular fingerprint for medulloblastoma. Cancer Res (2003) 2.66
Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell (2003) 2.54
Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d. Nat Cell Biol (2003) 2.46
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet (2002) 2.46
Agrobacterium tumefaciens-mediated transformation of maize embryos using a standard binary vector system. Plant Physiol (2002) 2.43
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle (2005) 2.37
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol (2005) 2.24
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev (2005) 2.14
N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev (2004) 2.14
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A (2003) 2.07
Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci (2006) 2.00
E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell (2009) 1.98
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 1.92
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genomics (2011) 1.87
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol (2008) 1.87
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81
Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol (2003) 1.75
Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med (2002) 1.74
A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. Nat Struct Mol Biol (2004) 1.72
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol (2003) 1.66
Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev (2008) 1.65
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture. J Cell Biol (2004) 1.56
Trial design: The St. Jude Children's Research Hospital Cancer Survivors Tobacco Quit Line study. Contemp Clin Trials (2009) 1.55
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res (2007) 1.51
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood (2003) 1.51
Age-dependent in vivo conversion of mouse cochlear pillar and Deiters' cells to immature hair cells by Atoh1 ectopic expression. J Neurosci (2012) 1.51
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol (2013) 1.51
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol (2010) 1.50
Disenrollment and re-enrollment patterns in a SCHIP. Health Care Financ Rev (2002) 1.50
Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res (2003) 1.49
Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell (2003) 1.47
Development and cancer of the cerebellum. Trends Neurosci (2011) 1.47
N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proc Natl Acad Sci U S A (2006) 1.45
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2012) 1.39
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol (2011) 1.39
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed (2011) 1.39
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med (2011) 1.34
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res (2007) 1.34
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol (2008) 1.33
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther (2003) 1.31
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. J Biopharm Stat (2009) 1.29
Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res (2013) 1.28
The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res (2002) 1.26
Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer (2010) 1.26
Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein. Hybrid Hybridomics (2004) 1.25
Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol (2012) 1.25
Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21. Nat Chem Biol (2011) 1.24
p19(Ink4d) and p21(Cip1) collaborate to maintain the postmitotic state of auditory hair cells, their codeletion leading to DNA damage and p53-mediated apoptosis. J Neurosci (2007) 1.23
Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma. Mol Cancer Res (2009) 1.22
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood (2006) 1.22
Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Res (2003) 1.21
Pseudoscore-based estimation from biased observations. Stat Med (2007) 1.20
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20
Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (2010) 1.16
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol (2008) 1.15